Peptide Therapy for Ehlers-Danlos Syndrome: What Actually Helps, What Doesn’t, and What We Don’t Know Yet

Why EDS Makes Peptide Therapy Complicated

Before looking at individual peptides, there are two things that matter for every EDS patient considering this route.

1. The Acute Injury Problem

Almost all peptide healing studies use acute injury models: surgically severed rat tendons, chemically induced ulcers, or clean surgical wounds. These are useful for showing that a peptide promotes healing. But they are fundamentally different from EDS.

EDS involves chronic, systemic connective-tissue fragility. The tissue that heals is still made from genetically faulty collagen. A peptide that stimulates more collagen production may simply produce more defective collagen.

A murine model of classical EDS caused by collagen V haploinsufficiency demonstrated exactly this: tendon healing was not just slower — it was structurally and mechanically deficient. The repair tissue itself was weaker, not just delayed.

So the right framework is:

A peptide may improve the healing environment. It does not fix what the healed tissue is made of.

That means realistic expectations are essential. Faster wound closure? Plausible. Reduced inflammation after a subluxation? Maybe. Normal joint stability? No.

2. The MCAS Complication

Many hEDS patients also have Mast Cell Activation Syndrome (MCAS). Prevalence estimates vary — some studies suggest up to 25-30% of hEDS patients, though a 2025 multicenter review disputes the strength of this association. The debate is ongoing, but the practical implication is clear:

If you have MCAS or suspected MCAS alongside your EDS, peptide injections carry extra risk.

The FDA specifically flagged that BPC-157 “could trigger an immune response.” For someone with mast cell instability, subcutaneous injections of any peptide could theoretically trigger degranulation, histamine release, or flares.

This does not mean peptides are off the table for MCAS patients. It means:

• start with topical routes where possible (GHK-Cu)
• introduce one peptide at a time
• start at low doses
• watch for mast cell flare patterns (flushing, hives, GI surge, tachycardia)

3. The Comorbidity Reality: POTS, MCAS, and Fibromyalgia

EDS rarely travels alone. Many hEDS patients also live with POTS (postural orthostatic tachycardia syndrome), MCAS, and fibromyalgia. That triad changes the peptide calculus significantly because it means pain is coming from multiple systems at once:

1. Mechanical pain — joints subluxing, ligaments overstretched, tissue damage. This is the structural EDS layer. No peptide convincingly fixes it.
2. Neurogenic inflammation — nerve irritation from repetitive tissue injury, small-fiber neuropathy. BPC-157 and ARA-290 are the most discussed options here.
3. Central sensitization — the nervous system stuck in threat mode, amplifying every pain signal. This is the fibromyalgia layer. SS-31 may help by improving cellular energy, reducing the metabolic stress that feeds sensitization.
4. Immune-driven pain — mast cell activation creating inflammatory pain flares that feel disproportionate to any identifiable trigger. This is where KPV becomes relevant (covered below).

Understanding which layer dominates your pain on a given day changes which peptide — if any — is worth considering. Most EDS patients experience all four, but in different ratios.

This also explains why peptides alone are rarely enough for someone with the full comorbidity picture. They can address layers 2-4 to varying degrees. Layer 1 requires physical stabilization — and that work makes everything else more effective.

Symptom Map: Where Peptides Are Most Plausible

1. BPC-157: The One You Probably Came Here For

Let’s start with BPC-157 because it’s the peptide most EDS patients search for first. If you want the deep dive on mechanism and dosing, see our complete BPC-157 guide. Here we’ll focus on what matters specifically for EDS.

Why EDS Patients Are Interested

BPC-157 is a 15-amino-acid peptide derived from human gastric juice. The preclinical literature suggests it:

• enhances fibroblast survival and migration
• accelerates tendon and ligament healing
• modulates nitric oxide and angiogenic signaling
• protects GI mucosa
• reduces inflammatory signaling

For an EDS patient stuck in the cycle of micro-injury, incomplete recovery, re-injury, deconditioning, and more injury, a “healing accelerator” is an obvious draw.

What the Evidence Actually Shows

Animal evidence: Extensive. Dozens of rodent studies show accelerated healing of transected tendons, ligaments, muscles, and bone. BPC-157 promotes fibroblast migration, collagen synthesis, and angiogenesis. The preclinical data is consistent and robust.

Human evidence: Extremely limited. Only a few small pilot studies exist — intraarticular knee injections (16 patients, no control group), bladder injections for interstitial cystitis, and an IV safety study. A 2025 systematic review in orthopaedic sports medicine concluded BPC-157 “should not be recommended for clinical use” until rigorous trials are completed.

EDS-specific evidence: Zero.

That’s the core problem. BPC-157’s reputation is built on animal studies of acute injuries. EDS involves chronic, systemic connective-tissue fragility. Whether accelerating collagen production in genetically fragile tissue actually helps — or just builds more defective tissue faster — has never been studied.

What the EDS Community Reports

From Reddit, Inspire forums, and EDS Facebook groups, BPC-157 reports are mixed:

Positive: Reduced joint pain, faster recovery from subluxations, improved gut symptoms (especially oral BPC-157), bruises resolving faster.

Negative: Dizziness, migraines, stomach upset, anxiety, heart palpitations, insomnia, mood changes. Several reports of worsened symptoms in patients who also have MCAS.

The pattern: results are highly individualized. Some people report meaningful relief; others get nothing or adverse effects.

Regulatory Reality

BPC-157 is listed by the FDA as a Category 2 bulk drug substance that may present significant safety risks in compounding. Specific concerns include immunogenicity, peptide impurities, and lack of adequate human clinical safety data. It is not FDA-approved and cannot legally be prescribed as a drug.

That doesn’t prove it’s dangerous in every setting. But it means the “safe, natural healing peptide” framing common in marketing is stronger than the regulatory or clinical evidence supporting it.

Where BPC-157 Makes Sense in EDS

The most defensible use case:

• acute or subacute soft-tissue recovery (post-subluxation, post-sprain)
• tendon or ligament irritation flares
• GI symptom support, particularly oral BPC-157 for mucosal-healing purposes

Where It Does NOT Make Sense

• tightening globally lax joints
• correcting collagen architecture
• preventing recurrent dislocations
• anything related to vascular EDS

Bottom Line

Reasonable to discuss as an experimental adjunct for tendon, ligament, and GI symptoms. Not reasonable to call an EDS treatment. Famous far beyond its evidence.

2. GHK-Cu: The Strongest Evidence for Skin and Wound Symptoms

If BPC-157 is the peptide people search for first, GHK-Cu is the one that arguably deserves to be discussed first — at least for the skin and wound-healing symptoms that define many EDS subtypes.

Why It Matches EDS

Many EDS patients — especially classical or skin-predominant subtypes — deal with:

• slow wound closure
• widened or papyraceous scars
• fragile, easily torn skin
• poor tissue quality after procedures

GHK-Cu is a copper-binding tripeptide with a biological profile that overlaps directly with these problems:

• stimulates fibroblast activity
• supports collagen and glycosaminoglycan production
• modulates matrix metalloproteinases (the enzymes that remodel healing tissue)
• improves angiogenic signaling
• reduces inflammatory signaling in healing tissue

There’s an additional EDS-specific angle worth noting: copper is required for lysyl oxidase, the enzyme responsible for collagen cross-linking. Cross-linking is what gives collagen its tensile strength. GHK-Cu won’t change the type of collagen your body produces, but it may support stronger cross-linking of the collagen you do have. That’s a subtle but meaningful distinction for EDS patients.

What Makes GHK-Cu Different from Other Peptides Here

It has real human clinical data.

Not just animal studies. Not just forum reports. Actual placebo-controlled human trials:

• A randomized double-blind study showed 55.8% reduction in wrinkle volume compared to control
• 70% of volunteers showed collagen increases with topical GHK-Cu application, outperforming both vitamin C and retinoic acid
• Clinical measurements of 20-30% improvements in skin firmness after 12 weeks of topical use
• Animal models demonstrating 30-50% wound healing time reductions

This is still not EDS-specific evidence. But it’s a meaningfully stronger foundation than BPC-157’s “lots of rat studies” base.

Best Use Case in EDS

• superficial wound healing support
• scar-quality improvement
• post-procedure skin recovery
• general skin-fragility management

Topical application is the most evidence-grounded route, which is also an advantage for EDS patients concerned about injection-site reactions or MCAS triggers.

What It Probably Does NOT Do

• fix the underlying collagen defect
• normalize skin tensile strength in genetically fragile tissue
• prevent dislocations
• make vascular EDS safer

Bottom Line

Best overall evidence fit for skin fragility and wound-healing symptoms in EDS. Topical route reduces injection-related risks. Still indirect and adjunctive — but more defensible than most options discussed online.

3. TB-500 (Thymosin Beta-4): Strong Biology, but a Specific EDS Warning

TB-500 gets less attention than BPC-157, but the wound-repair biology behind it is arguably stronger than most people realize. The important caveat is that it carries a risk that matters specifically for hypermobile patients.

The Research Base

The research foundation here is actually thymosin beta-4, the naturally occurring actin-binding protein. TB-500 is the synthetic fragment sold in the research peptide market. That distinction matters — TB-500 is not identical to what was used in clinical trials.

Thymosin beta-4 is involved in:

• actin dynamics and cell migration
• keratinocyte and fibroblast movement
• angiogenesis
• wound contraction and remodeling
• organized collagen fiber deposition (less scarring)

Human Evidence

Unlike BPC-157, thymosin beta-4 has been tested in humans:

• Phase 2 trials for venous/stasis ulcers: 73 patients, double-blind, placebo-controlled. The 0.03% dose accelerated wound closure, with complete healing in ~25% within 3 months.
• Phase 2 trials in epidermolysis bullosa (another inherited tissue-fragility disorder): TB4 was safe and accelerated wound repair.
• Across trials, TB4 was reported as safe and well-tolerated.

This matters because epidermolysis bullosa shares something important with EDS: the underlying tissue is genetically fragile. Seeing positive results in that context makes the EDS extrapolation slightly less speculative than usual.

The Hypermobility Warning

Here’s the specific EDS concern:

Multiple community reports describe TB-500 increasing feelings of joint looseness or instability in hypermobile individuals.

This makes biological sense. If TB-500 promotes tissue remodeling and cell migration, it could theoretically increase tissue laxity in joints that are already hypermobile. For someone whose core problem is too much joint range, that’s potentially counterproductive.

This is not proven in any clinical study. But it’s reported consistently enough in patient communities that it deserves mention, especially since most peptide content ignores it entirely.

Best Use Case in EDS

• skin wound recovery
• recurrent soft-tissue injury recovery
• recovery after tendon or fascial strain
• situations where wound quality (not joint stability) is the priority

Where to Be Cautious

• patients whose dominant symptom is joint instability (may worsen laxity)
• never frame it as a fix for hEDS joint problems
• never extrapolate to vascular EDS

Bottom Line

More legitimate wound-repair evidence than BPC-157 (thanks to actual Phase 2 trials of thymosin beta-4). But the reported laxity increase is a real concern for hypermobile patients. Use with eyes open.

4. SS-31: The Most Serious Fatigue Peptide

A lot of EDS patients are less interested in scar quality than in one brutal daily problem: fatigue that doesn’t match what they did.

Not tiredness. The kind of fatigue that overlaps with exercise intolerance, post-exertional crashes, orthostatic symptoms, and the persistent sense of running on a half-charged battery.

Why Fatigue in EDS Is Hard to Treat

EDS fatigue is multifactorial. It can involve chronic pain, poor sleep, dysautonomia, deconditioning, GI and nutritional issues, autonomic stress, and possibly mitochondrial inefficiency. No honest article should reduce it to one pathway.

But mitochondrial-targeted peptides keep coming up because part of the symptom pattern looks bioenergetic — and SS-31 (elamipretide) has real human data to back the mechanism.

What SS-31 Does

SS-31 is a cardiolipin-targeting tetrapeptide that improves mitochondrial membrane function. Mechanistically:

• stabilizes the inner mitochondrial membrane
• improves electron transport chain efficiency
• reduces mitochondrial oxidative stress
• supports ATP production

The Evidence

SS-31 has stronger clinical footing than most peptides discussed in EDS contexts:

• A randomized human trial showed improved skeletal muscle mitochondrial ATP production after a single dose
• On September 19, 2025, the FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome, a rare mitochondrial disorder — making it the first FDA-approved mitochondria-targeted therapeutic
• Trials in primary mitochondrial myopathy have produced real (though mixed) disease-program data

SS-31 is also widely available from research peptide vendors, separate from the pharmaceutical formulation.

How It Relates to EDS

SS-31 is best understood as a fatigue and exercise-intolerance peptide, not a connective-tissue peptide. The symptom link is:

• low cellular energy availability
• poor muscular recovery
• exercise intolerance
• fatigue in patients where bioenergetics may be part of the picture

A Note on Sleep and DSIP

One underappreciated part of the fatigue-pain cycle: poor sleep amplifies everything. Pain sensitivity increases, autonomic regulation worsens, and recovery slows. DSIP (delta sleep-inducing peptide) is sometimes discussed as indirect fatigue and pain support through sleep quality improvement. The evidence is thin and the mechanism is not well characterized, but for EDS patients whose fatigue tracks closely with poor sleep, it’s worth being aware of. It’s not a primary recommendation — just a footnote in the fatigue conversation.

The Limits

• no EDS-specific trials
• no evidence it improves joint stability or tissue quality
• EDS fatigue is multifactorial — not every case has a mitochondrial component
• will not help if fatigue is primarily from pain, sleep disruption, or dysautonomia

Bottom Line

The most clinically serious fatigue peptide available. If your dominant EDS symptom is energy and exercise tolerance rather than wound healing or joint pain, SS-31 is where the real human evidence lives. But it’s still an extrapolation in EDS.

5. ARA-290 (Cibinetide): Future Watch for Neuropathic Symptoms

This is the most speculative section, but it connects to an under-discussed EDS problem: small-fiber neuropathy.

Research has documented small-fiber neuropathy in 58-70% of hEDS patients who undergo formal testing. That may explain symptoms that don’t feel purely mechanical: burning pain, allodynia, temperature sensitivity, autonomic instability, skin pain that doesn’t match any structural finding.

What ARA-290 Does

ARA-290 (cibinetide) is an 11-amino-acid peptide that activates the innate repair receptor. In a Phase 2b randomized trial in sarcoidosis-associated small-fiber neuropathy (64 subjects, double-blind), the 4 mg dose produced:

• a statistically significant ~23% increase in corneal nerve fiber area
• increased skin nerve fiber regeneration
• clinically meaningful pain reduction in moderate-to-severe patients
• no significant safety issues

Why It Matters for EDS

Sarcoidosis is not EDS. But the target — small-fiber neuropathy causing neuropathic pain — is the same problem. If ARA-290 can regenerate small nerve fibers and reduce neuropathic symptoms, there’s a rational basis for interest from EDS patients whose pain has a neuropathic component.

The Limits

ARA-290 is not widely available from research peptide vendors at this point. It is not an accessible option for most people reading this article today. Consider it a concept to watch rather than something to act on now.

Bottom Line

Intellectually the most interesting option if your dominant symptom is neuropathic pain rather than structural damage. Not yet practical for most people.

6. KPV: The MCAS and Immune-Driven Pain Peptide

KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). It doesn’t get the attention BPC-157 does, but for EDS patients whose pain has a significant immune or inflammatory component — especially those with concurrent MCAS — it may be the most directly relevant peptide that most EDS content ignores entirely.

Why It Matters for the EDS Comorbidity Picture

Many EDS patients describe pain flares that don’t match any mechanical trigger. The hip didn’t sublux. Nothing tore. But the pain surged anyway — sometimes after eating, after stress, after a temperature change, or for no identifiable reason at all.

That pattern often points to immune-mediated inflammation, particularly mast cell activation. When mast cells degranulate, they release histamine, prostaglandins, cytokines, and other inflammatory mediators that:

• sensitize pain receptors
• increase local inflammation
• amplify existing pain signals
• trigger GI symptoms, flushing, and autonomic instability

For someone with EDS + MCAS, a significant portion of daily pain may be immune-driven rather than mechanical. That’s the lane KPV operates in.

What KPV Does

KPV has strong anti-inflammatory signaling properties. Research — primarily in inflammatory bowel disease and skin inflammation models — shows it:

• suppresses NF-kB activation (a master inflammatory switch)
• reduces pro-inflammatory cytokine production
• calms immune-driven tissue inflammation
• may reduce mast-cell-mediated inflammatory cascades

Where the Evidence Stands

KPV has been studied in IBD and dermatitis models, not in EDS or MCAS directly. The human evidence is early. But the biological rationale is straightforward: if a significant portion of your pain is inflammatory and immune-driven rather than structural, reducing that inflammatory signaling should reduce that portion of your pain.

This is especially relevant because MCAS-driven inflammation can make everything else worse — BPC-157 works less well when the immune system is flooding the area with inflammatory mediators. KPV may help quiet that noise so other interventions (peptide or otherwise) can function.

Best Use Case in EDS

• pain flares that seem disproportionate to mechanical triggers
• MCAS-driven inflammatory symptoms (flushing, GI surges, diffuse aching)
• systemic inflammation that worsens with stress, food triggers, or hormonal shifts
• as a foundational layer to calm immune noise before adding other peptides

The Limits

• no EDS-specific trials
• no MCAS-specific trials
• human data is early-stage
• will not help mechanical pain from subluxations or joint instability directly

Bottom Line

The most relevant peptide for the immune-driven pain layer that most EDS content overlooks. If your pain flares don’t match mechanical triggers and you have MCAS or suspect it, KPV deserves attention before or alongside the “healing” peptides.

What the EDS Community Actually Reports

Peptide discussions in EDS communities (Reddit r/ehlersdanlos, Inspire EDS forum, Facebook groups) follow a consistent pattern:

What people report positively:

• Reduced chronic joint pain and faster recovery from subluxations
• Improved gut symptoms, especially with oral BPC-157
• Bruises resolving faster
• Some improvement in general recovery capacity

What people report negatively:

• Extreme dizziness, migraines, and stomach upset
• Anxiety, panic attacks, and mood changes
• Heart palpitations and insomnia
• TB-500 specifically increasing joint looseness in some hypermobile individuals
• Flares in patients with concurrent MCAS

The consistent theme: Results are highly individualized. Product quality varies enormously. And as one Inspire forum member put it: “There’s definitely more info on peptide therapy than five years ago, but not a lot relating to patients with connective tissue disorders.”

That last point is the honest summary of where things stand.

Which Peptide for Which Symptom?

What Claims Should You Be Skeptical Of?

If you see any of these claims, the source is not being honest with you:

• “Peptides treat EDS”
• “BPC-157 tightens loose joints”
• “TB-500 fixes connective tissue disorders”
• “GHK-Cu rebuilds normal collagen in EDS”
• “This peptide stack will stop your dislocations”
• “Growth hormone peptides will strengthen your connective tissue”
• “Any peptide reduces rupture risk in vascular EDS”

The accurate version:

Some peptides may improve specific downstream symptoms in EDS — particularly wound healing, soft-tissue recovery, GI irritation, and fatigue. Direct EDS evidence is limited for all of them, and no peptide has been shown to correct the underlying connective-tissue disorder.

That is less exciting than most peptide marketing. It is also much closer to the truth.

If You Decide to Try Peptides: Practical Guidance for EDS Patients

This section is not medical advice. It’s a framework for approaching peptide experimentation as carefully as possible if you choose to go this route.

Start with the lowest-risk option

Topical GHK-Cu is the most evidence-grounded, lowest-risk starting point. No injection. No systemic exposure. If your primary symptoms include skin fragility, poor wound healing, or scar quality, this is where to begin.

One peptide at a time

Do not stack BPC-157 + TB-500 + GHK-Cu all at once. You will have no idea what’s helping, what’s hurting, or what’s doing nothing. Introduce one peptide, give it 2-4 weeks, and assess before adding anything else.

Start low on dosing

EDS patients may respond differently than the general population. If you’re using injectable peptides, start at the low end of commonly discussed dose ranges. See our dosage calculator for reconstitution math.

Watch for MCAS reactions

If you have known or suspected MCAS, monitor for: flushing, hives, GI surge, tachycardia, or any pattern that resembles a mast cell flare after injection. Consider premedicating with your usual MCAS protocol if you have one.

Keep your doctor in the loop

Especially if you are on medications for dysautonomia, pain management, or any EDS-related comorbidity. Peptides can interact with medications through shared pathways (particularly nitric oxide modulation with BPC-157).

Source matters enormously

Peptides are unregulated research chemicals. Purity, contamination, and actual peptide content vary wildly between vendors. Before purchasing anything:

• Read our 2026 vendor review for independent third-party testing analysis
• Learn how to read a Certificate of Analysis so you can verify what you’re getting
• See our equipment guide for everything you need for safe preparation and administration

If you’re new to peptide preparation, our reconstitution guide walks through the process step by step.

Avoid growth hormone peptides for joint stability

IGF-1, IGF-1 LR3, CJC-1295, ipamorelin, and other growth hormone secretagogues are sometimes marketed for tissue growth and recovery. For EDS patients, these are generally not ideal. They can increase tissue volume without improving stability, potentially worsening laxity. Growth without structural integrity is counterproductive when your joints already move too far.

Know what peptides can’t replace

Peptides work best as one layer in a broader approach. For most EDS patients, the biggest quality-of-life gains come from:

• EDS-informed physical therapy — stabilization and isometrics, not stretching. If PT ever made you worse, you likely had a therapist unfamiliar with hypermobility.
• Mast cell stabilization — if MCAS isn’t controlled, nothing works well. Pain, POTS, and fibro all flare when mast cells are active.
• Low-Dose Naltrexone (LDN) — not a peptide, but worth mentioning because it comes up constantly in EDS communities for good reason. LDN reduces microglial activation in the central nervous system, which directly addresses the central sensitization (fibromyalgia) layer of EDS pain. Many patients describe it as: “Pain is still there, but it’s quieter.” If you haven’t discussed LDN with your doctor, it may be worth a conversation before or alongside any peptide experimentation.
• Proprioceptive support — bracing, compression, and taping for high-risk joints during flares.

Peptides can reduce background inflammation, shorten flares, and support recovery. But they work better when the immune system and nervous system are already being addressed.

Be honest with yourself about results

The placebo effect is real, and it’s powerful in chronic pain conditions. Give yourself a defined trial period. Track specific symptoms. If you don’t see meaningful improvement after a reasonable run, the peptide probably isn’t doing what you hoped.

Final Verdict

If the goal is to identify the most realistic peptide options for EDS-related symptoms:

Tier 1: Most Defensible

GHK-Cu — Best overall fit for skin and wound symptoms. Human clinical data exists (non-EDS). Topical route minimizes risk. If your EDS symptoms are primarily skin-related, this is the strongest starting point.

Tier 2: Reasonable to Explore with Realistic Expectations

BPC-157 — Most popular for tendon, ligament, and GI symptoms. Extensive preclinical data, very limited human data. Famous beyond its evidence. Worth trying for acute soft-tissue recovery with eyes wide open about the evidence gaps.

TB-500 — Better wound-repair evidence than BPC-157 (Phase 2 human trials for thymosin beta-4). But the reported joint-laxity increase is a specific concern for hypermobile patients. Better suited for wound healing than joint recovery.

SS-31 — The most clinically serious fatigue peptide. Real human ATP production data and an FDA-approved mechanism. If energy and exercise tolerance are your dominant symptoms, this is where the strongest evidence lives. See our mitochondrial peptides guide for more.

KPV — The MCAS and immune-driven pain peptide. If your pain flares don’t correlate with mechanical triggers and you have MCAS or significant inflammatory symptoms, KPV addresses a layer that the “healing” peptides miss entirely. Early evidence, but strong biological rationale for this population.

Tier 3: Watch List

ARA-290 (cibinetide) — Compelling for neuropathic and small-fiber symptoms. Phase 2b human data exists. Not yet practical for most people.

The Single Most Important Point

Peptide therapy in EDS is symptom management, not disease treatment. The underlying connective-tissue defect remains. The tissue that heals is still built from the same genetic blueprint.

That does not make symptom management worthless — far from it. If a peptide helps your wounds close faster, reduces your tendon flares, calms your gut, or gives you more energy to get through the day, that has real value in a condition where small improvements compound.

Just don’t let anyone tell you it’s a cure. It isn’t.

Key References

1. Malfait F, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017. PMID: 28306229
2. Johnston JM, et al. Collagen V haploinsufficiency in a murine model of classic Ehlers-Danlos syndrome is associated with deficient structural and mechanical healing in tendons. J Orthop Res. 2017. PMID: 28387435
3. Fernandez A, et al. Small fibre neuropathy in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder. J Intern Med. 2022. PMC9796626
4. Cazzato D, et al. Small fiber neuropathy is a common feature of Ehlers-Danlos syndromes. Neurology. 2016. PMC4940063
5. Seneviratne SL, et al. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017. PMC9022617
6. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. PMID: 29401622
7. Wang X, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. 2017. PMID: 28370978
8. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PMID: 30915550
9. BPC-157 systematic review in orthopaedic sports medicine. PMC. 2025. PMC12313605
10. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA.gov
11. Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study. Ann N Y Acad Sci. 2007. PMID: 17495250
12. Thymosin beta-4 Phase 2 trial in epidermolysis bullosa. ClinicalTrials.gov NCT00311766
13. Roshanravan B, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide. PLoS One. 2021. PMID: 34264994
14. FDA grants accelerated approval to first treatment for Barth syndrome. September 19, 2025. Johns Hopkins Hub
15. Culver DA, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss. Invest Ophthalmol Vis Sci. 2017. PMID: 28475703
16. Abel L, et al. Skin fragility and wound management in Ehlers-Danlos syndromes. Clin Exp Dermatol. 2024. PMID: 38767179
17. Hertel AK, et al. Cardiovascular Symptoms, Dysautonomia, and Quality of Life in Hypermobile Ehlers-Danlos Syndrome. Curr Cardiol Rev. 2024. PMID: 38275067

Related Reading

• GHK-Cu Complete Guide
• BPC-157 Complete Guide
• TB-500 Complete Guide
• BPC-157 vs TB-500 Comparison
• 2026 Peptide Vendor Review
• Peptide Reconstitution Guide
• Peptide Equipment Guide
• COA Verification Guide